Sandoz Canada Makes Its Mark In Oncology Biosimilars
Two Launches Delivered Following Approvals
Sandoz Canada is continuing to expand its biosimilars footprint with entry into oncology, while also broadening its presence for autoimmune disorders like rheumatoid arthritis.
You may also be interested in...
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.
Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.
A dedicated website will spearhead a public education campaign initiated by Sandoz Canada for biosimilars, as their influence and presence continue to grow in the North American market. Sandoz itself is planning a portfolio of five products by the middle of 2021.